Diabetic Retinopathy Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 11.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Diabetic Retinopathy Market Analysis
The Diabetic Retinopathy Market is poised to grow at a CAGR of 11.5% during the study period, 2022-2027.
The COVID-19 pandemic led to disruption in not only the research and development activities of other therapies and drugs for medical conditions other than COVID-19 but also impacted the treatment procedures and supply chain of the pharmaceuticals and medical devices around the world which also impacted the studied market of diabetic retinopathy. However, lockdown led to the sudden transition to online activities which not only involved work but also education and entertainment and this led to increase in the screen time of individuals along with usage of vision correction devices such as contact lenses and spectacles. Further, the COVID-19 pandemic is expected to have a long-term impact on the people as today also a significant number of daily activities are being performed online which may have a negative impact on the eyes and led to increase in the demand for vision correction drugs and devices, thus positively impacting the market.
Certain factors that are driving the market growth include the rising prevalence of diabetes and blindness due to the same, growing geriatric population base, increasing technological advancements in diabetic retinopathy surgical instruments.
Diabetic retinopathy (DR) is a leading cause of vision-loss globally. The most clinically important risk factors for progression to vision loss include the duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure have been shown to be effective in preventing vision loss due to DR. There is an increasing burden of diabetic retinopathy across the globe. The increasing burden of diabetes is also driving the growth of market. As per "Diabetic retinopathy screening: a short guide" published by World health Organization in 2020, the prevalence of any retinopathy in persons with diabetes is 35% while proliferative (vision-threatening) retinopathy is 7%. Additionally, the International Diabetes Federation Diabetes Atlas, 10th edition 2021 reported that in 2021, globally there are about 536,600,000 people with diabetes, and it is estimated to reach 783,700,000 by the year 2045. such growing burden of diabetes rises the risk of diabetes retinopathy and thus, expected to drive the growth of market.
Additionally, the services launched for the diagnosis and improvement in diagnosis is also driving the growth of market in the country. For Instance, in December 2021, Eyenuk, Inc in collaboration with Discovery Health has launched a new Diabetic Retinopathy Screening Benefit nationwide in South Africa, powered by the cutting-edge EyeArt Artificial Intelligent System. It helps in enabling the detection of the onset of diabetic retinopathy as early as possible. Such benefits plans and services increases the early detection of the diseases and hence drives the growth of market.
According to the research study published in May 2021, titled 'A deep learning system for detecting diabetic retinopathy across the disease spectrum', the screening of retina can help in the early detection of the diabetic retinopathy which can be used for administering the timely treatment, and as per the study, the DeepDR system achieved high sensitivity and specificity in diabetic retinopathy grading and with the introduction of the image quality sub-network and lesion-aware sub-network into DeepDR, it improved the diagnostic performance and more closely followed the thought process of ophthalmologists. Thus, the DeepDR has great potential to improve the accessibility and efficiency of diabetic retinopathy screening which may be incorporated in the future devices and drive the growth in the studied market.
Hence, the rising prevalence of diabetic retinopathy, along with the growing awareness and concern over it, are expected to drive the market growth over the forecast period. however, lack of skilled ophthalmologists and extended time for product approvals are expected to hinder the market.
Diabetic Retinopathy Market Trends
This section covers the major market trends shaping the Diabetic Retinopathy Market according to our research experts:
Proliferative diabetic retinopathy is Expected to Hold Significant Market Share in the Type Segment
Proliferative diabetic retinopathy (PDR) is the most advanced stage of diabetic retinopathy. At this stage, circulation problems deprive the retina of oxygen. As a result, new, fragile blood vessels can begin to grow in the retina and into the vitreous, the gel-like fluid that fills the back of the eye. The new blood vessels may leak blood into the vitreous, clouding vision.
Symptoms include progressive loss of vision, particularly in those who are not properly followed or treated. The major risk factors for PDR include the duration of diabetes. Hence, the rising prevalence of diabetes is directly contributing to a further increase in the prevalence of PDR.
The rising research and development activities for developing effective diagnostic and therapeutic methods for proliferative diabetic retinopathy will further drive the segment growth. For instance, "Mi-RNA-93 and Mi-RNA-152 in the Diagnosis of Type 2 Diabetes and Diabetic Retinopathy" published in January 2022, MiR-93 and miR-152 can differentiate between patients with diabetes and those with diabetic retinopathy. Both miRNAs can be potential biomarkers for diabetes and diabetic retinopathy, and specifically for proliferative diabetic retinopathy.
Additionally, the study "Vitreous Inflammatory Cytokines and Chemokines, Not Altered After Preoperative Adjunctive Conbercept Injection, but Associated With Early Postoperative Macular Edema in Patients With Proliferative Diabetic Retinopathy" published in March 2022, preoperative adjunctive anti-VEGF drug (Conbercept) on vitreous inflammatory cytokines and chemokines profiles and cytokines were associated with early macular edema (ME) after surgery for patients with proliferative diabetic retinopathy (PDR). Thus, studies proving the efficacies to existing treatments will further increase its adoption, thus driving the market.
Thus, due to the above-mentioned factors, the studied segment is expected to drive the segment growth during study period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to be significantly driven during the study period owing to the factors such as the rising prevalence of diabetes and blindness , the growing geriatric population, and increasing technological advancements in diabetic retinopathy surgical instruments.
Over the past decade, the prevalence of diabetes in North America has increased. People with diabetes are at risk for diabetic retinopathy. Diabetic retinopathy is the leading cause of new cases of blindness among adults aged 20 to 74 years in the United States. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2020 around 4.1 million Americans are affected with diabetic retinopathy, and nearly 900,000 Americans are threatened with vision-damaging retinopathy. Hence the increasing number of people living with diabetic retinopathy is expected to contribute to market growth across the country.
In December 2021, the Tec's system for early detection of Diabetic Retinopathy assisted by Artificial Intelligence (DRAI) was included in the 30 projects with potential to contribute to the Global Partnership on Artificial Intelligence (GPAI). Diabetic retinopathy is damage caused by the disease to small blood vessels in the retina's light-sensitive tissue. It is one of the most common causes of blindness. DRAI tackles 3 diabetic retinopathy problems in Mexico which are high rates of diabetes, lack of ophthalmologists (42.5 ophthalmologists per 1 million people) and few early detection program. Providing solutions for all three primary issues prevalent in the country the inclusion of Tec system will likely to boost the growth of the market in coming future.
Awareness is one of the key issues related with diabetic retinopathy treatment and diagnostics. For instance, in December 2021 a paper published in National Library of Medicine "Prevalence of and Factors Associated with Diabetic Retinopathy in Patients with Diabetes Mellitus at Siriraj Hospital - Thailand's Largest National Tertiary Referral Center" stated that there is no conclusive study that proves direct correlation between people suffering from diabetic retinopathy and going for continuous eye screening. Early detection is one of the factors that could provide the treatment for the patients suffering from diabetic retinopathy disorders at an early stage.
Thus, due to the above-mentioned factors, the North American region is expected to be significantly driven during the study period.
Diabetic Retinopathy Industry Overview
The Diabetic Retinopathy market is moderately competitive and consists of a few major players. Companies like Alimera Sciences, Allergan plc, BCN Peptides, F. Hoffmann-La Roche Ltd, Glycadia Pharmaceuticals, Kowa Group, Novartis AG, and Oxurion NV. The players are adopting strategies such as partnerships and acquisitions, product launches, research and development activities, and rising investments to strengthen their presence in the market.
Diabetic Retinopathy Market Leaders
-
Regeneron Pharmaceuticals, Inc.
-
Alimera Sciences
-
Oxurion NV.
-
Abbvie Inc.
-
F. Hoffmann-La Roche Ltd
*Disclaimer: Major Players sorted in no particular order
Diabetic Retinopathy Market News
- In June 2022, Regeneron Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application (sBLA) for every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR).
- In February 2022, REGENXBIO Inc. announced additional positive interim data from the ongoing Phase II ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery.
Diabetic Retinopathy Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Diabetes and Blindness Due to The Same
- 4.2.2 Growing Geriatric Population Base
- 4.2.3 Increasing Technological Advancements in Diabetic Retinopathy Surgical Instruments
-
4.3 Market Restraints
- 4.3.1 Lack of Skilled Ophthalmologists
- 4.3.2 Extended Approval Time for Drugs
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market SIze by Value - in USD Million)
-
5.1 By Type
- 5.1.1 Proliferative Diabetic Retinopathy
- 5.1.2 Non-proliferative Retinopathy
-
5.2 By Management Approach
- 5.2.1 Anti-VEGF Drug
- 5.2.2 Intraocular Steroid Injection
- 5.2.3 Laser Surgery
- 5.2.4 Vitrectomy
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Alimera Sciences
- 6.1.2 AbbVie Inc. (Allergan plc)
- 6.1.3 BCN Peptides
- 6.1.4 F. Hoffmann-La Roche Ltd (Genentech)
- 6.1.5 Glycadia Pharmaceuticals
- 6.1.6 Ocuphire Pharma
- 6.1.7 Novartis AG
- 6.1.8 Regeneron Pharmaceuticals Inc
- 6.1.9 Oxurion NV.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Diabetic Retinopathy Industry Segmentation
As per the scope of the report, diabetic retinopathy refers to a diabetes complication that affects eyes, DR results in damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Initially, diabetic retinopathy may cause no symptoms or only mild vision problems. But eventually, it can cause blindness. The Diabetic Retinopathy Market is segmented by Type (Proliferative diabetic retinopathy, Non-proliferative retinopathy), Management Approach (Anti-VEGF Drug, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy) and Geography (North America, Europe, Asia - Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type | Proliferative Diabetic Retinopathy | |
| Non-proliferative Retinopathy | ||
| By Management Approach | Anti-VEGF Drug | |
| Intraocular Steroid Injection | ||
| Laser Surgery | ||
| Vitrectomy | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Diabetic Retinopathy Market Research FAQs
What is the current Global Diabetic Retinopathy Market size?
The Global Diabetic Retinopathy Market is projected to register a CAGR of 11.5% during the forecast period (2024-2029)
Who are the key players in Global Diabetic Retinopathy Market?
Regeneron Pharmaceuticals, Inc., Alimera Sciences, Oxurion NV., Abbvie Inc. and F. Hoffmann-La Roche Ltd are the major companies operating in the Global Diabetic Retinopathy Market.
Which is the fastest growing region in Global Diabetic Retinopathy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Diabetic Retinopathy Market?
In 2024, the North America accounts for the largest market share in Global Diabetic Retinopathy Market.
What years does this Global Diabetic Retinopathy Market cover?
The report covers the Global Diabetic Retinopathy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Diabetic Retinopathy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Diabetic Retinopathy Industry Report
Statistics for the 2024 Diabetic Retinopathy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Diabetic Retinopathy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
